Amylyx Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $-665 | $416 | $-1,022 | $88,643 |
Gross Profit | -665 | -393 | -8,648 | -28,078 |
EBITDA | -40,494 | -39,237 | -53,227 | -121,815 |
EBIT | -40,654 | -39,458 | -53,435 | -122,130 |
Net Income | -37,546 | -72,704 | -72,700 | -118,793 |
Net Change In Cash | -665 | 416 | -1,022 | 88,643 |
Free Cash Flow | -59,028 | -41,551 | -66,669 | -556 |
Cash | 77,391 | 71,839 | 74,999 | 170,552 |
Basic Shares | 68,593 | 68,091 | 68,024 | 67,854 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $87,371 | $380,786 | $22,230 | $285 |
Gross Profit | 45,215 | 355,345 | 19,237 | 285 |
EBITDA | -290,976 | 39,890 | -200,854 | -82,636 |
EBIT | -291,880 | 38,802 | -201,341 | -82,688 |
Net Income | -301,743 | 49,271 | -198,375 | -87,879 |
Net Change In Cash | 87,371 | 380,786 | 22,230 | 285 |
Cost of Revenue | 12,930 | |||
Free Cash Flow | -167,804 | 10,678 | -182,397 | -75,152 |
Cash | 77,391 | 170,201 | 62,526 | 50,191 |
Basic Shares | 68,142 | 69,991 | 66,512 | 57,864 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.55 |
2024-09-30 | -$1.07 |
2024-06-30 | -$0.73 |
2024-03-31 | -$0.12 |
